CERUBIDINE

Post-LOE

daunorubicin hydrochloride

Hikma

ANDAINJECTIONINJECTABLE

Approved

Feb 1995

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CERUBIDINE (daunorubicin hydrochloride) by Hikma is clinical pharmacology mechanism of action daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action. Approved for leukemia. First approved in 1995.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Mechanism of Action Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action. Daunorubicin forms complexes with DNA by intercalation between base pairs. It inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II…

Worked on CERUBIDINE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

CERUBIDINE

Mechanism of Action

Indications (1)